February 26, 2017
Recommended Topic Related To:


"The combination drug elbasvir/grazoprevir (Zepatier, Merck) reduced viral load in patients with chronic hepatitis C virus (HCV) infection being treated for opioid addiction in a randomized controlled trial.

The favorable outcom"...





In INFERGEN trials, the maximum overdose reported was a dose of 150 mcg INFERGEN administered subcutaneously in a subject enrolled in a phase 1 advanced malignancy trial. The subject received 10 times the prescribed dosage for three days and experienced a mild increase in anorexia, chills, fever, and myalgia. Increases in ALT (15 IU/L to 127 IU/L), aspartate transaminase (AST) (15 to 164 IU/L), and lactic dehydrogenase (LDH) (183 IU/L to 281 IU/L) were reported. These laboratory values returned to normal or to the subjects baseline values within 30 days.


INFERGEN is contraindicated in patients with:

Additionally, ribavirin is contraindicated in:

  • women who are pregnant
  • men whose female partners are pregnant
  • patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)
  • patients with hypersensitivity to ribavirin or any other component of the product
  • patients with creatinine clearance < 50 mL/min
This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 6/17/2013


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.